PHASE I STUDY OF AUTOLOGOUS ACUTE MYELOGENOUS LEUKEMIA (AML) CELLS CONTAINING LENTIVIRUS ENGINEERING EXPRESSION OF IL-12
- Registry ID
- OZM-068
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- UNIVERSITY HEALTH NETWORK
- Start date
- 2016-05-20
- Last update
- 2016-01-07
Conditions
- ACUTE MYELOGENOUS LEUKEMIA
Related clinical trials
- A PHASE 1/2 FIRST IN HUMAN STUDY OF THE MENIN-MLL (KMT2A) INHIBITOR KO 539 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ENTOSPLETINIB IN COMBINATION WITH INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN ADULTS WITH NEWLY DIAGNOSED NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA
- A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA
- A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION.
- RISK-STRATIFIED THERAPY FOR ACUTE MYELOID LEUKEMIA IN DOWN SYNDROME
- RANDOMIZED PHASE II STUDY TO ASSESS THE ROLE OF NIVOLUMAB AS SINGLE AGENT TO ELIMINATE MINIMAL RESIDUAL DISEASE AND MAINTAIN REMISSION IN ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS AFTER CHEMOTHERAPY
View on source registry